Scarica l'app Stockscreener
7.98
8.06%
-0.70
Dopo l'orario di chiusura:
7.99
0.010
+0.13%
Precedente Chiudi:
$8.68
Aprire:
$8.67
Volume 24 ore:
1.47M
Relative Volume:
1.12
Capitalizzazione di mercato:
$661.57M
Reddito:
Utile/perdita netta:
$-34.98M
Rapporto P/E:
-8.6749
EPS:
-0.9199
Flusso di cassa netto:
$-32.77M
1 W Prestazione:
-15.64%
1M Prestazione:
-33.05%
6M Prestazione:
-19.88%
1 anno Prestazione:
+195.56%
Intervallo 1D:
$7.95
$8.67
Intervallo di 1 settimana:
$7.95
$9.56
Portata 52W:
$2.61
$15.10
Immix Biopharma Inc Stock (IMMX) Company Profile
Nome
Immix Biopharma Inc
Settore
Industria
Telefono
(888) 958-1084
Indirizzo
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
7.98 | 661.57M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-07-22 | Iniziato | Needham | Buy |
| 2026-06-18 | Iniziato | BofA Securities | Buy |
| 2026-03-25 | Iniziato | Morgan Stanley | Overweight |
| 2026-03-09 | Iniziato | Citizens | Mkt Outperform |
| 2026-02-09 | Iniziato | Mizuho | Outperform |
Immix Biopharma Inc Borsa (IMMX) Ultime notizie
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Immix Biopharma to Participate in the 45th Annual J.P.... - t.co
San Francisco will host Immix Biopharma’s presentation Jan. 11–14. - Stock Titan
Immix Biopharma Prices $125 Million Equity Offering - The Globe and Mail
Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock - TradingView
Immix Biopharma closes $117.1m stock offering By Investing.com - Investing.com Nigeria
Immix Biopharma Closes $117.1 Million Underwritten Registered Offering - Quiver Quantitative
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock - GlobeNewswire
Immix plans to use about $117 million for treatment development and company operations - Stock Titan
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed? - Yahoo Finance
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial - Yahoo Finance
Immix Biopharma prices $125M stock offering at $11 per share - Investing.com Nigeria
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock - GlobeNewswire
All 25 new patients had a complete response or tested negative for remaining disease - Stock Titan
IMMXAL Amyloidosis CAR T Platform And Regulatory Tailwinds Will Drive Long-Term Opportunity - Simply Wall Street
Immix Biopharma (Nasdaq:IMMX)Stock Analysis - Simply Wall Street
Immix Biopharma (NasdaqCM:IMMX) Stock Price - Simply Wall Street
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeBeta Neutral Pair - dars.gov.et
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeSign of Strength - dars.gov.et
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeIndex Put Call - siam.in
Immix (IMMX) Today: Moves 1.32% Lower to $13.48 at the Close; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordUp Down Volume - vinanet.vn
Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat
Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat
Immix (IMMX) Quarterly Scorecard: The Available Figures Are Largely in Line on the Day; Session Move: Shares Fall 1.21% in the Current UpdatePre-Earnings Setup - vinanet.vn
Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month HighStill a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX) - The Globe and Mail
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Canada
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com India
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com UK
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire
Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat
HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - marketscreener.com
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - Moomoo
IMMIX BIOPHARMA, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20 - Bitget
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Australia
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com South Africa
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Nigeria
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com India
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com
Immix Biopharma Inc Azioni (IMMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immix Biopharma Inc Azioni (IMMX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
2.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):